SOUTH SAN FRANCISCO, Calif.,
May 5, 2020 /PRNewswire/ -- Portola
Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or
"Portola") today announced that it
is cancelling its webcast and conference call to discuss the
Company's financial results for the first quarter ended
March 31, 2020 that was previously
scheduled for Monday, May 11, 2020,
at 4:30 p.m. ET (1:30 p.m.
PT).
This cancellation is due to the announcement on May 5, 2020, that Portola has entered into a definitive merger
agreement to be acquired by Alexion Pharmaceuticals, Inc. (NASDAQ:
ALXN). Portola will issue a press
release reporting its first quarter 2020 financial results on
Monday, May 11, 2020. The press
release will be available on the Company's website at
www.portola.com.
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic conditions. The Company's first
two commercialized products are Andexxa® [coagulation
factor Xa (recombinant), inactivated-zhzo], marketed in
Europe as Ondexxya®
(andexanet alfa), and Bevyxxa® (betrixaban). The Company
also is advancing cerdulatinib, a SYK/JAK inhibitor being developed
for the treatment of hematologic cancers. Founded in 2003 in
South San Francisco, California,
Portola has operations in
the United States and Europe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-cancels-first-quarter-2020-financial-results-webcast-and-conference-call-following-agreement-to-be-acquired-by-alexion-301053068.html
SOURCE Portola Pharmaceuticals, Inc.®